Factor V Leiden improves in vivo hemostasis in murine hemophilia models

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 12, 2005, Pages 2730-2737

  Schlachterman, A ^a   Schuettrumpf, J ^a   Liu, J H ^a   Freguia, C F ^a   Toso, R ^a   Poncz, M ^a,b   Camire, R M ^a,b   Arruda, V R ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Factor V Leiden; Hemophilia; Murine model; Thrombophilia; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; FERRIC CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT; BLOOD CLOTTING TIME; CAROTID ARTERY INJURY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM INJURY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; IN VIVO STUDY; LASER; MICROCIRCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS; THROMBUS;

ANIMALS; BLOOD COAGULATION; CAROTID ARTERY INJURIES; DISEASE MODELS, ANIMAL; FACTOR V; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; MICE; MICE, INBRED STRAINS; MICROCIRCULATION; MICROSCOPY, VIDEO; MUSCLE, SKELETAL;

EID: 29244443415     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01639.x     Document Type: Article

References (40)

1. Roberts HR, Hoffman M. Hemophilia A and hemophilia B. In: Beutler E, Coller B, Lichtman M, Kipps T, Seligsohn U, eds. Hematology, 6th edn. New York, NY: McGraw Hill, 2001: 1639-57.
2. Tuddenham EG, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne JM, Giannelli F, Antonarakis SE, Cooper DN. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 1994; 22: 3511-33.
3. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
4. Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs T, Duprat I, Sultan Y. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat. haemophiles@cch.ap-hop-paris.fr. Haemophilia 2000; 6: 23-32.
5. Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.
6. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101: 20-30.
7. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
8. Bertina R, Koeleman B, Kostner B, Rosendaal F, Dirven R, Ronde H, Velden P, Reitsma P. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
9. Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, Hoyer L, Kaufman RJ, Ginsburg D. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183-7.
10. Lee DH, Walker IR, Teitel J, Poon MC, Ritchie B, Akabutu J, Sinclair GD, Pai M, Wu JW, Reddy S, Carter C, Growe G, Lillicrap D, Lam M, Blajchman MA. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83: 387-91.
11. Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among 'severe' hemophiliacs with a 'milder' bleeding diathesis. Thromb Haemost 1995; 74: 1255-8.
12. Arruda V, Annichino-Bizzacchi J, Antunes S, Costa F. Association of severe hemophilia A and factor V Leiden: report of three cases. Haemophilia 1996; 2: 51-53.
13. Chang J, Weinman AF, Thompson AR. Factor V Arg/Gln306 has no dominant influence of the severity of hemophilia when inherited concurrently. Throm Haemost 1995; 73: 1368.
14. Escuriola Ettingshausen C, Halimeh S, Kurnik K, Schobess R, Wermes C, Junker R, Kreuz W, Pollmann H, Nowak-Gottl U. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85: 218-20.
15. van't Veer C, Golden NJ, Kalafatis M, Simioni P, Bertina RM, Mann KG. An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood 1997; 90: 3067-72.
16. Bos M, Meijerman D, Van der Zwaan C, Mertens K. Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma? J Thromb Haemost 2005; 3: 1-9.
17. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996; 88: 3815-23.
18. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem 1996; 271: 22949-52.
19. Parker AC, Mundada LV, Schmaier AH, Fay WP. Factor V Leiden inhibits fibrinolysis in vivo. Circulation 2004; 110: 3594-8.
20. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia. Nat Genet 1995; 10: 119-21.
21. Kung J, Hagstrom J, Cass D, Tai S, Lin HF, Stafford DW, High KA. Human FIX corrects the bleeding diathesis of mice with hemophilia B. Blood 1998; 91: 784-90.
22. Cui J, Eitzman D, Westrick R, Christie P, Xu Z, Yang A, Prurkayastha A, Yang T, Metz A, Gallagher K, Tyson J, Rosenberg R, Ginsburg D. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000; 96: 4222-6.
23. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW, High KA. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 2000; 1: 225-35.
24. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
25. Ravanat C, Freund M, Dol F, Cadroy Y, Roussi J, Incardona F, Maffrand J, Boneu B, Drouet L, Legrand C, Herbet J, Cazenave J. Cross-reactivity of human molecular markers for detection of pre-thrombotic states in various animal species. Blood Coag Fibrinol 1995; 6: 446-55.
26. Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 2004; 105: 2316-23.
27. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998; 97: 1002-8.
28. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002; 8: 1175-81.
29. Toso R, Camire RM. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J Biol Chem 2004; 279: 21643-50.
30. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92.
31. Rosen ED, Raymond S, Zollman A, Noria F, Sandoval-Cooper M, Shulman A, Merz JL, Castellino FJ. Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi. Am J Pathol 2001; 158: 1613-22.
32. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998; 92: 3035-41.
33. Sun H, Yang TL, Yang A, Wang X, Ginsburg D. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood 2003; 102: 2856-61.
34. Fernandez JA, Xu X, Liu D, Zlokovic BV, Griffin JH. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis 2003; 30: 271-6.
35. Uhrin P, Dewerchin M, Hilpert M, Chrenek P, Schofer C, Zechmeister-Machhart M, Kronke G, Vales A, Carmeliet P, Binder BR, Geiger M. Disruption of the protein C inhibitor gene results in impaired spermatogenesis and male infertility. J Clin Invest 2000; 106: 1531-9.
36. Esmon CT, Ding W, Yasuhiro K, Gu JM, Ferrell G, Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mather T, Laszik Z, Esmon NL. The protein C pathway: new insights. Thromb Haemost 1997; 78: 70-4.
37. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
38. Laszik Z, Mitro A, Taylor FB Jr, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 1997; 96: 3633-40.
39. Cawthern KM, van't Veer C, Lock JB, Di Lorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
40. Simioni P, Castoldi E, Lunghi B, Tormene D, Rosing J, Bernardi F. An underestimated combination of opposites resulting in enhanced thrombotic tendency. Blood 2005.